ALFQ adjuvanted HIV-1 envelope protein vaccination elicits durable functional antibody and cellular responses in nonhuman primates

Adjuvants play an important role in modulating antigen-specific immune responses. We conducted a comparative adjuvant immunogenicity study in Rhesus macaques using HIV-1 subtype B gp120 envelope protein, B.63521, formulated with aluminum hydroxide gel (AH), or a family of liposomal adjuvants known as Army Liposome Formulation (ALF). ALF comprises saturated phospholipids, cholesterol, and monophosphoryl lipid A. Inclusion of QS-21 or adsorption of the antigen to AH, followed by the addition of ALF, generates ALFQ and ALFA, while inclusion of both immunostimulants generates ALFQA. Priming with canarypox vector ALVAC, followed by boosting with ALVAC and gp120 formulated with each of the four adjuvants, resulted in ALFQ and ALFQA outperforming AH and ALFA vaccine formulations with a high frequency of antigen-specific plasma cells in the bone marrow, robust antibodies, and Env-specific polyfunctional CD8+ T cell responses. Transcriptomic analyses revealed upregulation of antiviral and innate immune pathways, thus highlighting ALFQ as a highly potent adjuvant.

• Publication year

  2025

• Venue

  npj Vaccines

• Publication date

  2025-12-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41541-025-01322-7PMID 41419739PMCID 12764542
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin/monophosphoryl lipid A nanoparticle

  2024cited by this paper
• SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial.

  2024cited by this paper
• mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

  2024cited by this paper
• Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial

  2024cited by this paper
• CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits

  2024cited by this paper
• Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates

  2024cited by this paper
• Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response

  2024cited by this paper
• Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies

  2024cited by this paper
• Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

  2024cited by this paper
• Saponin nanoparticle adjuvants incorporating Toll-like receptor agonists drive distinct immune signatures and potent vaccine responses

  2024cited by this paper
• Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.

  2024cited by this paper
• Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21

  2023cited by this paper
• Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Drive Distinct Immune Signatures and Potent Vaccine Responses

  2023cited by this paper
• SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies

  2023cited by this paper
• Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120

  2023cited by this paper
• Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques

  2023cited by this paper
• Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial

  2022cited by this paper
• NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

  2022cited by this paper
• First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults.

  2022cited by this paper
• HLA-B∗46 associates with rapid HIV disease progression in Asian cohorts and prominent differences in NK cell phenotype.

  2022cited by this paper
• Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.

  2021cited by this paper
• Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

  2021cited by this paper
• Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques

  2021cited by this paper
• Current approaches to HIV vaccine development: a narrative review

  2021influential reference
• Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1

  2021cited by this paper
• Using Adjuvants to Drive T Cell Responses for Next-Generation Infectious Disease Vaccines

  2021cited by this paper
• Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

  2021cited by this paper
• Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults

  2021cited by this paper
• SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

  2021influential reference
• 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates

  2020cited by this paper
• Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge

  2020cited by this paper
• Army Liposome Formulation (ALF) family of vaccine adjuvants

  2020cited by this paper
• Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype

  2019influential reference
• Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

  2019influential reference
• A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation

  2019cited by this paper
• A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials

  2019cited by this paper
• RTS,S/AS01 vaccine (Mosquirix™): an overview

  2019cited by this paper
• Differential Effect of Mucosal NKp44+ Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques

  2019cited by this paper
• Strong TH1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy

  2019cited by this paper
• Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques

  2019influential reference
• Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant

  2018cited by this paper
• Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans

  2018cited by this paper
• Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV

  2018cited by this paper
• Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell‐mediated cytotoxicity assay

  2018cited by this paper
• Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co‐adsorption of ALF or ALFQ adjuvant to the aluminum‐antigen complex

  2018cited by this paper
• Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

  2017cited by this paper
• Beyond binding: antibody effector functions in infectious diseases

  2017cited by this paper
• Adjuvant system AS01: helping to overcome the challenges of modern vaccines

  2017cited by this paper
• Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21

  2017influential reference
• HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

  2017cited by this paper
• Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys

  2015cited by this paper
• Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research

  2015cited by this paper
• COMPASS identifies T-cell subsets correlated with clinical outcomes

  2015cited by this paper
• HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities

  2014influential reference
• Trimmomatic: a flexible trimmer for Illumina sequence data

  2014influential reference
• Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

  2014cited by this paper
• Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

  2014cited by this paper
• The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential

  2013cited by this paper
• Molecular signatures of antibody responses derived from a systems biological study of 5 human vaccines

  2013cited by this paper
• Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

  2012cited by this paper
• Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

  2012cited by this paper
• Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion

  2012cited by this paper
• Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

  2012cited by this paper
• Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

  2012influential reference
• ADCC Develops Over Time during Persistent Infection with Live-Attenuated SIV and Is Associated with Complete Protection against SIVmac251 Challenge

  2012cited by this paper
• Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

  2012cited by this paper
• Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family

  2012cited by this paper
• High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses

  2011cited by this paper
• Competing interests

  2010cited by this paper
• A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.

  2010cited by this paper
• Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1

  2009cited by this paper
• edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

  2009influential reference
• Measuring HIV neutralization in a luciferase reporter gene assay.

  2009influential reference
• Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

  2009cited by this paper
• Fc receptor but not complement binding is important in antibody protection against HIV

  2007cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• An automated method for finding molecular complexes in large protein interaction networks

  2003cited by this paper
• Design and selection of vaccine adjuvants: animal models and human trials.

  2002cited by this paper

• No citing papers are available for this paper.